Savvy Advisors Inc. Purchases Shares of 1,245 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Savvy Advisors Inc. bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,245 shares of the biopharmaceutical company's stock, valued at approximately $887,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Norges Bank purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $802,036,000. Amundi boosted its holdings in shares of Regeneron Pharmaceuticals by 45.8% in the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after buying an additional 487,489 shares during the period. Loomis Sayles & Co. L P increased its position in shares of Regeneron Pharmaceuticals by 33.4% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock worth $1,122,168,000 after acquiring an additional 393,997 shares in the last quarter. Proficio Capital Partners LLC raised its holdings in shares of Regeneron Pharmaceuticals by 92,865.3% during the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock valued at $156,284,000 after acquiring an additional 219,162 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock valued at $1,726,940,000 after acquiring an additional 155,369 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Analysts Set New Price Targets

REGN has been the topic of several recent analyst reports. Citigroup dropped their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. BMO Capital Markets cut their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a report on Tuesday, February 4th. Sanford C. Bernstein reduced their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. Piper Sandler dropped their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research report on Monday, January 27th. Finally, Leerink Partners upgraded Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their price target for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $963.56.

Regeneron Pharmaceuticals Price Performance

REGN stock traded up $13.88 during midday trading on Friday, reaching $563.16. 827,663 shares of the company's stock traded hands, compared to its average volume of 712,904. The company has a 50-day simple moving average of $645.94 and a two-hundred day simple moving average of $740.52. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market cap of $61.57 billion, a price-to-earnings ratio of 14.71, a PEG ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals, Inc. has a 1-year low of $525.99 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. During the same quarter last year, the company posted $11.86 EPS. The company's quarterly revenue was up 10.3% compared to the same quarter last year. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.63%. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.